Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study - Summary - MDSpire
Advertisement
Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study
To determine whether the baseline peripheral blood CD4/CD8 ratio predicts grade ≥2 immune-related adverse events (irAEs) within 30 days of initiating single-agent PD-1/PD-L1 blockade in advanced lung cancer.
Key Findings:
51 out of 202 patients (25%) developed grade ≥2 irAEs.
Baseline CD4/CD8 ratio < 1.65 was present in 63% of patients with early irAEs vs. 36% of controls (p < 0.001).
CD4/CD8 ratio < 1.65 remained a significant predictor of early irAEs (OR 3.03; 95% CI 1.57–5.84).
Hypertension and diabetes were also associated with increased risk of irAEs (ORs provided in the source).
Interpretation:
Remove unsupported conclusions.
Limitations:
Single-center study may limit generalizability.
Retrospective design may introduce bias.
Systematic inter-run coefficient-of-variation data for flow cytometry were not captured.
